Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Paroxetine derivative
US8933100B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8933100-B2 |
| Application number | US-201313752638-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 29, 2013 |
| Priority date | Jan 31, 2012 |
| Publication date | Jan 13, 2015 |
| Grant date | Jan 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound represented by Formula (1), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of paroxetine and has an improved CYP inhibitory effect: wherein R 1 is a hydrogen atom or C 1-6 alkyl group.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound represented by formula (1), or a pharmacologically acceptable salt thereof: wherein R 1 is a hydrogen atom or C 1-6 alkyl group. 2. The compound or pharmacologically acceptable salt thereof according to claim 1 , wherein R 1 is a hydrogen atom. 3. The compound or pharmacologically acceptab…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- C07D405/12Primary
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8933100B2 cover?
- A compound represented by Formula (1), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of paroxetine and has an improved CYP inhibitory effect: wherein R 1 is a hydrogen atom or C 1-6 alkyl group.
- Who is the assignee on this patent?
- Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D405/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).